Management of Hepatic Encephalopathy

Treatment Approach

• The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver recommend adding rifaximin 550 mg twice daily to lactulose therapy for patients with persistent hepatic encephalopathy, as this combination has been shown to maintain remission in patients who have experienced one or more bouts of overt hepatic encephalopathy while on lactulose treatment 1, 2, 3, 4, 5
• Lactulose should be continued with a dose titrated to achieve 2-3 soft stools daily, as recommended by the KASL clinical practice guidelines 2

Supportive Measures

• The European Association for the Study of the Liver suggests considering additional supportive measures, including oral branched-chain amino acids (BCAA) and intravenous L-ornithine L-aspartate (LOLA) or albumin, as well as ensuring adequate nutrition with 1.2-1.5 g/kg protein intake daily and implementing small frequent meals (4-6 times daily including a night snack) 2
• Long-term treatment with rifaximin does not increase the risk of Clostridium difficile infection compared to control groups 2

Precipitating Factors and Patient Education

• It is essential to identify and manage precipitating factors of hepatic encephalopathy, including gastrointestinal bleeding, infection, constipation, excessive protein intake, dehydration, renal dysfunction, electrolyte imbalance, psychoactive medications, and acute hepatic injury 2
• Implementing structured educational intervention for the patient and caregivers about medication effects and side effects, importance of adherence, early symptoms and signs of recurring hepatic encephalopathy, and actions to take if recurrence begins is crucial, as recommended by the Liver International guidelines and the European Association for the Study of the Liver 5, 1, 2

Long-term Management

• If the patient continues to have recurrent episodes of hepatic encephalopathy despite optimal medical therapy, liver transplantation should be considered, especially given the poor prognosis (overall survival rate after an episode of overt hepatic encephalopathy is 42% at 1 year and 23% at 3 years) 2
• Rifaximin can be considered for prophylaxis of hepatic encephalopathy prior to non-urgent TIPS placement, significantly reducing the incidence of overt HE episodes (34% vs 53%) when started 14 days prior to TIPS placement, as recommended by the European Association for the Study of the Liver 3

Pharmacology and Safety

• Rifaximin is a safe and effective oral nonsystemic antibiotic for patients with liver disease, with minimal systemic absorption (<0.4%) making it suitable for patients with hepatic impairment 6, 6
• Rifaximin reduces mortality in hepatic encephalopathy (RR: 0.50; 95% CI, 0.31–0.82) and improves recovery rates (RR: 0.59; 95% CI, 0.46–0.76) 6
• Rifaximin should be used with caution in patients with severe hepatic impairment (Child-Pugh Class C) and in patients with MELD scores >25, with monitoring for Clostridium difficile-associated diarrhea and drug interactions, particularly with warfarin 5, 7, 8

Dosage and Administration

Special Considerations

• Rifaximin may be considered for pediatric patients with multiple recurrences following standard antibiotic treatments, but it is not a first-line treatment and is used when conventional treatments have failed 10
• Alternative antibiotics, such as doxycycline, ciprofloxacin, amoxicillin-clavulanic acid, and cefoxitin, may be considered if rifaximin is unavailable or ineffective, with metronidazole being less effective 11
• Non-absorbed antibiotics like rifaximin may be preferable to absorbed antibiotics to reduce the risk of systemic resistance 11